Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease

• Published in: Journal of medical virology Vol. 52; no. 2; pp. 215 - 218
• Main Authors: Lee, Shou-Dong, Chan, Cho-Yu, Yu, May-Ing, Wang, Yuan-Jen, Chang, Full-Young, Lo, Kwang-Juei, Safary, Assad
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 01.06.1997; Wiley-Liss
• Subjects: Adolescent; Adult; Alanine Transaminase - blood; Biological and medical sciences; Chronic Disease; chronic liver disease; Female; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Hepatitis A Antibodies; Hepatitis A Vaccines; Hepatitis Antibodies - blood; Hepatitis B - immunology; Hepatitis B - metabolism; Hepatitis C - immunology; Hepatitis C - metabolism; Human viral diseases; Humans; inactivated hepatitis A vaccine; Infectious diseases; Male; Medical sciences; Microbiology; Middle Aged; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Vaccines, Inactivated - adverse effects; Vaccines, Inactivated - immunology; Viral diseases; Viral hepatitis; Viral Hepatitis Vaccines - adverse effects; Viral Hepatitis Vaccines - immunology; Virology; Human; Hepatitis A virus; Picornaviridae; Toxicity; Hepatic disease; Vaccine; Infection; Virus; Viral hepatitis B; Chronic; Immunogenicity; Viral disease; Digestive diseases; Viral hepatitis C
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/(SICI)1096-9071(199706)52:2<215::AID-JMV16>3.0.CO;2-J

The safety and immunogenicity of inactivated hepatitis A vaccine was evaluated in patients with chronic liver disease. Sixty hepatitis A virus antibody (anti‐HAV) seronegative patients A virus antibody (anti‐HAV) seronegative patients with chronic liver disease (56 chronic hepatitis B and four chronic hepatitis C) and from 17 to 47 years of age received a dose of 1440 ELISA units of the inactivated hepatitis A vaccine at month 0, and a booster at month 6. Anti‐HAV seroconversion (⩾ 33 mlU/mL) was 57.6% (34/59) on day 15, and reached 93.2% (55/59) 1 month after primary vaccination. At month 6, the seropositivity of anti‐HAV decreased before the booster to 69.0% (40/58). All vaccinees had measurable titers of anti‐HAV 1 month after booster vaccination, and were still seropositive at month 12. After initial vaccination, the geometric mean titers of anti‐HAV among vaccine responders were 158, 264, 74, 1309, and 409 mlU/ml at day 15 and months 1, 6, 7, and 12. Overall, 59.7% (71/119) of the vaccine doses administered were followed by mostly minor reactions. The majority of symptoms reported were local, all of which resolved within 3 days after vaccination. No significant changes in serum liver enzyme levels were detected after vaccination. Thus, an inactivated hepatitis A vaccine was safe in patients with chronic liver disease while the immune response was inferior to that observed in healthy subjects reported in a previous study. J. Med. Virol. 52:215–218, 1997. © 1997 Wiley‐Liss, Inc.